John Wiley & Sons, Inc.

SHERPA: Unknown

People

  1. Shah
    Shah
  2. Shaha
    Shaha
  3. Patel
    Patel
  4. Lee
    Lee
  5. Ganly
    Ganly
  6. Wong
    Wong
  7. Pfister
    Pfister
  8. Sherman
    Sherman
  9. Cohen
    Cohen
  10. McBride
    McBride

Groups

  1. Surgery (202)
  2. Department of Medicine (161)
  3. Survivorship Research (113)
  4. Hematologic Malignancies, Division of (100)
  5. Center for Hematologic Malignancies (94)
  6. Population Sciences Research Program (45)
  7. Solid Tumor Oncology Division (45)
  8. Radiation Oncology, Department of (44)
  9. Center for Pancreatic Cancer Research (39)
  10. Department of Pathology and Laboratory Medicine (39)
Search Within
Formats
  1. Journal Article (387)
  2. Conference Paper (35)
  3. Review (28)
  4. Meeting Abstract (27)
  5. Research Letter (18)
  6. Correspondence (12)
  7. Guidelines (9)
  8. Editorial (3)
Groups
  1. Surgery (202)
  2. Department of Medicine (161)
  3. Survivorship Research (113)
  4. Hematologic Malignancies, Division of (100)
  5. Center for Hematologic Malignancies (94)
  6. Population Sciences Research Program (45)

More Groups

People
  1. Jatin Shah (83)
  2. Ashok Shaha (61)
  3. Snehal Patel (50)
  4. Nancy Lee (40)
  5. Ian Ganly (39)
  6. Dennis Kraus (37)

More People

Years
  1. 2025 (12)
  2. 2024 (19)
  3. 2023 (28)
  4. 2022 (18)
  5. 2021 (29)
  6. 2020 (28)

More Years

Publications
  1. Head & Neck (234)
  2. American Journal of Hematology (127)
  3. Progress in Clinical and Biological Research (60)
  4. Genetic Epidemiology (32)
  5. Journal of Cellular Physiology (25)
  6. Journal of Genetic Counseling (14)

More Publications

Results (519)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Rebuttal to comment on “concurrent carboplatin and paclitaxel definitive radiation therapy for locally advanced head and neck cancer”
    Correspondence

    Han, J. E.; Zakeri, K.; Michel, L.; Sherman, E. J.; Lee, N. Y.
    Head & Neck (2024)

    Fulltext@MSK | Save
  • Ecoritamab SSC with rituximab + lenalidomide in patients with relapsed or refractory follicular lymphoma, including patients with POD24: Updated results from EPCORE NHL-2
    Meeting Abstract

    Merryman, R. W.; Belada, D.; Sureda, A.; Leppä, S.; Vermaat, J. S. P.; Holte, H.; Hutchings, M.; Lugtenburg, P.; de Vos, S.; Abrisqueta, P.; more...
    American Journal of Hematology (2023)

    Fulltext@MSK | Save
  • Evasion to CD47-targeted phagocytosis in DLBCL
    Meeting Abstract

    Fernandez-Pacheo, F.; Busik, J.; Man, J.; Kolesnick, R.; Wendel, H. G.
    American Journal of Hematology (2023)

    Fulltext@MSK | Save
  • Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed/refractory follicular lymphoma who received ≥2 prior therapies: Updated results from a pivotal phase II study
    Meeting Abstract

    Bartlett, N. L.; Sehn, L. H.; Matasar, M. J.; Schuster, S. J.; Assouline, S. E.; Giri, P.; Kuruvilla, J.; Canales, M.; Dietrich, S.; Fay, K.; more...
    American Journal of Hematology (2023)

    Fulltext@MSK | Save
  • Subcutaneous epcoritamab with R-CHOP in previously untreated high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated results from EPCORE NHL-2
    Meeting Abstract

    Falchi, L.; Clausen, M. R.; Offner, F.; de Vos, S.; Brody, J. D.; Kim, M. L.; Snauwaert, S.; Cordoba, R.; Oki, T.; Bykhovski, I.; more...
    American Journal of Hematology (2023)

    Fulltext@MSK | Save
  • A subgroup analysis from MagnetisMM-3: the efficacy and safety of elranatamab by age and frailty in patients with relapsed or refractory multiple myeloma
    Meeting Abstract

    Raje, N.; Leleu, X.; Lesokhin, A. M.; Mohty , M.; Nooka, A.; Leip, E.; Conte, U.; Vlqueira, A.; Manier, S.
    American Journal of Hematology (2023)

    Fulltext@MSK | Save
  • Bendamustine-based bridging versus standard of care approaches: A comparison of toxicity profiles of bridging therapy in multiple myeloma patients undergoing CAR T cell therapy
    Meeting Abstract

    Yan, L.; Sridevi, R.; Sheng, T.; Marcio, D.; Shambavi, R.; Sundar, J.; Adriana, R.
    American Journal of Hematology (2023)

    Fulltext@MSK | Save
  • Pooled analysis of MagnetisMM studies: Efficacy and safety of elranatamab in patients with relapsed or refractory multiple myeloma (RRMM) previously exposed to B-cell maturation antigen (BCMA)-directed therapies
    Meeting Abstract

    Nooka, A. K.; Lesokhin, A. M.; Mohty, M.; Niesvizky, R.; Maise, C.; Arnulf, A.; Larson, S. M.; Asya, V. Y. N.; Leleu, X.; Karlin, L.; more...
    American Journal of Hematology (2023)

    Fulltext@MSK | Save
  • Clinical decision support for chemotherapy-induced neutropenia using a hybrid pharmacodynamic/machine learning model
    Journal Article

    Hughes, J. H.; Tong, D. M. H.; Burns, V.; Daly, B.; Razavi, P.; Boelens, J. J.; Goswami, S.; Keizer, R. J.
    CPT: Pharmacometrics and Systems Pharmacology (2023)

    Fulltext@MSK | Save
  • CAD/CAM-assisted ablative surgery and intraoperative brachytherapy for pediatric skull-base sarcomas
    Journal Article

    Lopez, J.; Subramanian, T.; Stambuk, H.; Schreyer, M.; Woods, R.; Scholfield, D.; Wong, R.; Cohen, M. A.; Shah, J.; Ganly, I.
    Head & Neck (2023)

    Fulltext@MSK | Save

    • John Wiley & Sons, Inc. – authorized name for: